Botox injections with and without general anesthesia for pediatric sialorrhea: A cost, efficacy, and safety analysis.
Abstract
[OBJECTIVE] Ultrasound-guided salivary gland Botulinum toxin A (Botox) injections are often used in pediatric patients with refractory sialorrhea, performed with or without general anesthesia. This study aims to compare outcomes and costs between these methods.
[STUDY DESIGN] Retrospective cohort study.
[SETTING] Tertiary children's hospital.
[METHODS] Patients with chronic sialorrhea refractory to medical therapy who underwent Botulinum toxin A injections between 2012 and 2023 under general anesthesia (n = 50; 126 injections) were compared to those performed without general anesthesia (n = 31; 116 injections). Sociodemographic factors, clinical history, and injection regimen were recorded. Available billing data from this time period was used to compare costs.
[RESULTS] Pediatric patients who underwent Botulinum toxin A injections without general anesthesia did not have statistically significant differences in post-injection cessation of anticholinergic medications (AOR = 0.980, [0.29, 3.29]), family-reported improvement in sialorrhea (AOR = 3.25, [0.58, 18.1]), admissions for aspiration pneumonia within the year (Coefficient = 0.260, [-0.22, 0.75]), or progression to sialorrhea surgery (AOR = 0.374, [0.07, 2.16]) compared to those performed under general anesthesia. Amongst patients who underwent repeat injections, there were no significant differences in the average number of injections (p = 0.41) or time between injections (p = 0.16). Botulinum toxin A injections performed in the outpatient setting ($1374.49) had significantly lower costs compared to injections performed under general anesthesia ($5077.13) (p < 0.001).
[CONCLUSION] Pediatric patients undergoing Botulinum toxin A injections with and without general anesthesia have similar efficacy and quality outcomes. Exploring the advantages of Botulinum toxin A injections without general anesthesia could lead to improved access, reduced risks of general anesthesia, and reduced costs to the medical system.
[STUDY DESIGN] Retrospective cohort study.
[SETTING] Tertiary children's hospital.
[METHODS] Patients with chronic sialorrhea refractory to medical therapy who underwent Botulinum toxin A injections between 2012 and 2023 under general anesthesia (n = 50; 126 injections) were compared to those performed without general anesthesia (n = 31; 116 injections). Sociodemographic factors, clinical history, and injection regimen were recorded. Available billing data from this time period was used to compare costs.
[RESULTS] Pediatric patients who underwent Botulinum toxin A injections without general anesthesia did not have statistically significant differences in post-injection cessation of anticholinergic medications (AOR = 0.980, [0.29, 3.29]), family-reported improvement in sialorrhea (AOR = 3.25, [0.58, 18.1]), admissions for aspiration pneumonia within the year (Coefficient = 0.260, [-0.22, 0.75]), or progression to sialorrhea surgery (AOR = 0.374, [0.07, 2.16]) compared to those performed under general anesthesia. Amongst patients who underwent repeat injections, there were no significant differences in the average number of injections (p = 0.41) or time between injections (p = 0.16). Botulinum toxin A injections performed in the outpatient setting ($1374.49) had significantly lower costs compared to injections performed under general anesthesia ($5077.13) (p < 0.001).
[CONCLUSION] Pediatric patients undergoing Botulinum toxin A injections with and without general anesthesia have similar efficacy and quality outcomes. Exploring the advantages of Botulinum toxin A injections without general anesthesia could lead to improved access, reduced risks of general anesthesia, and reduced costs to the medical system.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 6 | |
| 시술 | botox
|
보툴리눔독소 주사 | dict | 2 | |
| 합병증 | anesthesia
|
scispacy | 1 | ||
| 약물 | [OBJECTIVE] Ultrasound-guided salivary gland Botulinum toxin A
|
scispacy | 1 | ||
| 약물 | [-0.22,
|
scispacy | 1 | ||
| 질환 | sialorrhea
|
C0037036
Sialorrhea
|
scispacy | 1 | |
| 질환 | chronic sialorrhea
|
C4012480
Chronic sialorrhea
|
scispacy | 1 | |
| 질환 | pneumonia
|
C0032285
Pneumonia
|
scispacy | 1 | |
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | children
|
scispacy | 1 | ||
| 기타 | Botulinum toxin A
|
scispacy | 1 |
MeSH Terms
Humans; Sialorrhea; Botulinum Toxins, Type A; Retrospective Studies; Male; Female; Child; Anesthesia, General; Treatment Outcome; Adolescent; Cost-Benefit Analysis; Child, Preschool; Ultrasonography, Interventional; Cohort Studies
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.